1 results match your criteria: "Department of Ophthalmology and Visual Science at Yale University School of Medicine[Affiliation]"
Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma.
Ocul Oncol Pathol
January 2020
Department of Ophthalmology and Visual Science at Yale University School of Medicine, New Haven, Connecticut, USA.
Background: Conjunctival melanoma is a potentially lethal malignancy of the ocular surface. There have been no therapeutic advancements made in the past several decades despite increasing prevalence of the disease.
Methods: The authors report the case of a 52-year-old Caucasian male with unresectable, recurrent conjunctival melanoma with V600 mutation who was treated with systemic BRAF/MEK inhibition.